**Name of Journal:** *World Journal of Stem Cells*

**Manuscript NO:** 82793

**Manuscript Type:** REVIEW

**Advancements in adipose-derived stem cell therapy for skin fibrosis**

Liu YX *et al*. ASC therapy for skin fibrosis

Yu-Xin Liu, Jia-Ming Sun, Chia-Kang Ho, Ya Gao, Dong-Sheng Wen, Yang-Dan Liu, Lu Huang, Yi-Fan Zhang

**Yu-Xin Liu, Jia-Ming Sun, Chia-Kang Ho, Ya Gao, Dong-Sheng Wen, Yang-Dan Liu, Lu Huang, Yi-Fan Zhang,** Department of Plastic and Reconstructive Surgery, Shanghai Ninth People's Hospital, Shanghai Jiao Tong University, Shanghai 200011, China

**Author contributions:** Liu YX and Sun JM wrote the manuscript; Liu YX, Sun JM, Liu YD, Wen DS and Huang L contributed significantly to manuscript preparation; Liu YX and Sun JM wrote the manuscript; Sun JM contributed to data presentation; Ho CK, Gao Y and Zhang YF revised the manuscript; All authors have read and approved the final manuscript.

**Supported by** National Natural Science Foundation of China, No. 81772103 and No. 82172234; and Shanghai Clinical Research Center of Plastic and Reconstructive Surgery supported by Science and Technology Commission of Shanghai Municipality, China, No. 22MC1940300.

**Corresponding author: Yi-Fan Zhang, MD, PhD, Associate Professor,** Department of Plastic and Reconstructive Surgery, Shanghai Ninth People's Hospital, Shanghai Jiao Tong University, No. 639 Zhizaoju Road, Shanghai 200011, China. zhangyifan82@126.com

**Received:** December 28, 2022

**Revised:** March 30, 2023

**Accepted:** April 13, 2023

**Published online:**

**Abstract**

Pathological scarring and scleroderma, which are the most common conditions of skin fibrosis, pathologically manifest as fibroblast proliferation and extracellular matrix (ECM) hyperplasia. Fibroblast proliferation and ECM hyperplasia lead to fibrotic tissue remodeling, causing an exaggerated and prolonged wound-healing response. The pathogenesis of these diseases has not been fully clarified and is unfortunately accompanied by exceptionally high medical needs and poor treatment effects. Currently, a promising and relatively low-cost treatment has emerged-adipose-derived stem cell (ASC) therapy as a branch of stem cell therapy, including ASCs and their derivatives-purified ASC, stromal vascular fraction, ASC-conditioned medium, ASC exosomes, *etc.*, which are rich in sources and easy to obtain. ASCs have been widely used in therapeutic settings for patients, primarily for the defection of soft tissues, such as breast enhancement and facial contouring. In the field of skin regeneration, ASC therapy has become a hot research topic because it is beneficial for reversing skin fibrosis. The ability of ASCs to control profibrotic factors as well as anti-inflammatory and immunomodulatory actions will be discussed in this review, as well as their new applications in the treatment of skin fibrosis. Although the long-term effect of ASC therapy is still unclear, ASCs have emerged as one of the most promising systemic antifibrotic therapies under development.

**Key Words:** Adipose-derived stem cell; Cicatrix, hypertrophic; Keloid; Scleroderma, localized; Stromal vascular fraction; Exosomes

Liu YX, Sun JM, Ho CK, Gao Y, Wen DS, Liu YD, Huang L, Zhang YF. Advancements in adipose-derived stem cell therapy for skin fibrosis. *World J Stem Cells* 2023; In press

**Core Tip:** Pathological scarring and scleroderma are the most common conditions of skin fibrosis with high medical needs and poor therapeutic effects. Adipose-derived stem cell (ASC) therapy has emerged as a promising treatment for skin fibrosis. Here, we discuss the possible mechanism of skin fibrosis as well as the latest research about the mechanism of ASC therapy and its application in treating these conditions. ASC therapy provides a brand-new insight into the treatment of skin fibrosis.

**INTRODUCTION**

Skin fibrosis is characterized by fibroblast proliferation and extracellular matrix (ECM) deposition. In severe cases, it can lead to pathological changes in the skin, such as keloid and hypertrophic scars (HS), systemic sclerosis (SSc), and scleroderma[1,2]. The fact that there are no practical disease-modifying therapies for those diseases and current treatment is mainly toward managing symptoms and relieving complications calls for a new therapy[3,4].

Since 2001, when adipose-derived stem cells (ASCs) were first characterized, ASCs have been broadly studied and applied as the most promising sources of cells with regenerative and multilineage characteristics[5]. In recent years, various ASC derivatives, which are rich in not only ASCs but also other cellular and tissue components, have been seen as possible alternatives to ASCs and have received increasing attention for exploring their potential applications. Due to their immunomodulatory properties and abundance of growth factors[6,7], ASCs and their derivatives have become new remedies in the treatment of skin fibrosis[8-10].

In this review, we discuss the mechanism of skin fibrosis and the mechanism of ASC therapy. We then summarize the application of ASCs and their derivatives in skin fibrosis. Finally, we retrospectively describe the safety of ASC therapy and predict the future of skin fibrosis treatments.

**Mechanism of skin fibrosis**

Many fundamental studies exploring the molecular mechanisms underlying fibrosis have revealed a large number of genes, molecules, and cell types that may contribute to this problem[11,12].

***Keloid and HS***

The pathogenesis of keloids and HS is not fully understood due to the complex dynamic process of wound healing. However, among all the factors that stimulate fibroblasts to differentiate into myofibroblasts and produce excessive amounts of collagen and ECM, the role of the inflammatory response is increasingly considered important[1,11,13]. Downregulation of proinflammatory cytokines such as interleukin 6 (IL-6) and IL-8[14] and upregulation of anti-inflammatory cytokines such as IL-10 may reduce scar tissue formation[15]. Additionally, inflammatory cells such as macrophages, T cells, and mast cells, all increase and take part in a variety of biological activities in keloids and HS [1,16]. Although multiple intracellular signaling pathways such as Smad, signal transducer and activator of transcription 3, and extracellular signal-regulated kinase 3, are involved in hypertrophic scar formation, transforming growth factor-β (TGF-β)/Smad is thought to be a driving force[17,18]. Thus, the basic purpose of current prevention and therapy methods is still to reduce inflammatory processes[19].

***SSc and scleroderma***

SSc is an immune-mediated rheumatic disease that is characterized by excessive collagen from myofibroblasts in the skin and some internal organs, [microangiopathy](https://webvpn.shsmu.edu.cn/https/77726476706e69737468656265737421e7e056d234336155700b8ca891472636a6d29e640e/topics/pharmacology-toxicology-and-pharmaceutical-science/microangiopathy), and impairment of the humoral and [cellular immunity](https://webvpn.shsmu.edu.cn/https/77726476706e69737468656265737421e7e056d234336155700b8ca891472636a6d29e640e/topics/biochemistry-genetics-and-molecular-biology/cellular-immunity) system[20,21]. Scleroderma features, without the involvement of internal organs, are similar to SSc[4]. SSc pathogenesis involves early vasculopathy and innate and adaptive immune system dysfunction[12]. Initial vasculopathy and immune system dysfunction are both involved in SSc pathogenesis and cause SSc inflammation and tissue fibrosis[22]. Immune cells, endothelial cells, and fibroblasts interact with each other and release cytokines and growth factors[21]. Workers are convinced that type-1-interferon and interferon-inducible genes play a role in SSc pathogenesis[23]. Additional important factors include platelet-derived growth factor, endothelin 1, insulin-like growth factor 1, and TGF, which is thought to be a major regulator of fibrosis pathways[24]. Combined treatment that targets epigenetic/genetic, vascular, and immunologic defects and progressive fibrosis is urgently needed[12,21,25].

**Mechanism of ASC therapy**

ASCs have long been thought to have immune privileges as mesenchymal stromal cells, which do not induce a severe allogeneic response when injected into another organism[26,27]. However, they have been demonstrated to evoke cellular and humoral responses in vivo, which may lead to the rapid elimination of transplanted cells[27]. However, ASCs function primarily through a “hit-and-run mechanism” with consequently a small effect on therapeutic efficacy, at least in the short or middle term[28,29]. Indeed, most ASCs do not require cell-to-cell contact to function but rather function through paracrine mechanisms that release cytokines, growth factors, and extracellular microvesicles in the surrounding environment[30]. As reported, the therapeutic effect of ASCs and their derivatives depends on paracrine secretion[31-34]. ASC-secreted active substances such as cytokines[35], growth factors[36], chemokines[37], and extracellular vesicles[38], regulate the microenvironment around fibroblasts and themselves[39,40] (Figure 1).

***Regulation of the microenvironment***

**Immunomodulation and anti-inflammatory:** After injection, ASCs activate adaptive cellular responses, secreting IL-1, prostaglandin E2 (PGE2), IL-4 and IL-10, and TGF-β, which modulate and stimulate innate immune cells[41]. It was reported that ASCs suppress CD4+ and CD8+ T-cell expansion and differentiation while promoting regulatory T-cell proliferation and enhancing their immunosuppressive activity[42]. Additionally, ASCs secrete immunosuppressive substances such as nitric oxide, PGE2, hepatocyte growth factor (HGF), and indoleamine 2,3-dioxygenase, which downregulate TGF-β in skin fibrosis and attract bone marrow (BM) cells involved in tissue repair[43,44].

Despite their immunomodulatory ability, the anti-inflammatory effects of ASCs have been gaining increasing attention. ASCs can drive anti-inflammatory M2 macrophage polarization and ameliorate macrophage infiltration[34,45]. Additionally, in a rabbit model of HS, ASCs mediated the inhibition of M1-polarized macrophages and defection of inflammation. Moreover, the expression of inflammatory cytokines and proteins such as IL-6 and monocyte chemotactic protein-1, which affect inducible nitric oxide synthase and cyclooxygenase-2, was notably decreased in the treated groups[46-48].

**Angiogenic effects:** The angiogenic effects of ASCs have been broadly discussed with regard to myocardial infarction, nerve injury, and tissue transplantation[49-52]. The secretion of vascular endothelial growth factor (VEGF) as well as the transcription of angiogenic genes are improved by ASCs[52,53]. ASC transplantation greatly improves revascularization and tissue perfusion in ischemic scars by stimulating endotheliocyte proliferation in blood vessels, hastening the resumption of blood circulation, providing oxygen and nutrition, and improving scar texture[54]. There is also an interplay between ASCs and endothelial precursor cells (EPCs). Growth factors produced by ASCs, such as VEGF, increase the migration and survival of EPCs, while EPC-produced platelet-derived growth factor BB stimulates ASC proliferation and migration[36].

***Regulation of fibroblasts***

**Proliferation and differentiation:** Activated dermal fibroblasts change their phenotype into myofibroblasts in response to injury or stress, which increases their expression of α-smooth muscle actin (α-SMA) and contractile ability[55,56]. Previous studies have demonstrated that ASC conditioned medium (ASC-CM) contains abundant growth factors and cytokines, such as IL-10, adrenomedullin, and HGF[7,57]. HGF, proven to inhibit fibroblast differentiation into myofibroblasts, contributes to limiting the profibrotic functions of myofibroblasts[58,59]. It has also been reported that ectodysplasin-A2, insulin-like growth factor binding protein-related protein-1/insulin-like growth factor-binding protein-7 (IGFBP-rp1/IGFBP-7), and thrombospondin-1 are increased in concentration in serum-starved ASC-CM, which could play a role in the inhibition of fibrosis[60]. These ASC-secreted immunosuppressive substances suppress fibrosis by various mechanisms, including reducing the expression of TGF-β1 and collagen and promoting the expression of matrix metalloproteinases (MMP), thus significantly repressing the activity of fibroblasts *in vitro* and *in vivo*[34,61].

**Expression of ECM:** The synthesis of collagen, hyaluronic acid, and fibronectin by myofibroblasts, in particular, is essential for the prolonged and excessive formation of ECM constituents[56,62]. Inhibition of HS-derived fibroblast (HSF) proliferation and reduction in α-SMA, type I collagen, and type III collagen expression can partly explain the molecular mechanism of the effects of ASCs on HSs[46,63,64]. In another study, ASC-CM reduced the synthesis of collagen and the expression of connective tissue growth factor, fibronectin, and α-SMA[65]. However, in a coculture model of ASCs and normal human dermal fibroblasts, ASCs increased the formation of collagen types I, III, and VI in the ECM[66]. It appears that ASCs could target abnormal fibroblasts and reduce pathological deposition of ECM.

**ASC therapy application**

ASC therapy, including the application of ASCs and their derivatives, can be roughly divided into ASC-based therapy and stem cell-free therapy. ASC-based therapy is mainly composed of various ASCs and stromal vascular fractions (SVFs), which have been broadly studied and applied in the clinic (Figure 2). Stem cell-free therapy, such as exosomes and ASC-CM, is increasingly popular, with fewer moral and safety concerns.

***ASCs***

One of the most promising stem cell groups, ASCs, are abundant in adipose tissue, easy to extract, and have few adverse effects. Compared to BM-mesenchymal stem cells, ASCs exert potent anti-inflammatory and remodeling properties with similar therapeutic effects[30].

Intralesional injection of ASCs reduces the formation of scars while improving color quality and scar pliability, potentially leading to an effective and novel anti-scarring therapy[59,67,68]. These studies revealed that ASCs not only inhibited fibroblast proliferation and migration but also reduced the expression of molecules such as TGF-β1 and Notch-1. The antifibrotic effect on fibroblasts was most likely mediated by the inhibition of multiple intracellular signaling pathways[18,65].

As they are inherently heterogeneous, different ASC subgroups have been studied in the hope of finding suitable subgroups for specific diseases.

A subpopulation of ASCs that are positive for CD74+ possesses enhanced antifibrotic abilities both *in vitro* and *in vivo*. Additionally, CD74+ ASC-assisted fat grafts reduce dermal thickness and fibrosis in radiation-induced fibrosis mouse models[69]. Another CD73+ ASC subpopulation has expressed significantly lower levels of procollagen lysyl hydroxylase 1, a potent stimulator of fibrosis, showing better therapeutic effects on wound healing[70].

To modify or enhance some properties of ASCs and overcome the limitations of curative effects of ASCs only, ASCs are coated or activated with small molecule drugs or genetically overexpressing molecules that are involved in fibrosis formation.

After overexpressing MMP-3, ASCs-MMP-3 possess not only the ability of ASCs to accelerate wound healing but also the capability of MMP-3 to reduce scarring[71]. Compared with mASCs alone, migration ability and HGF production are significantly higher in mASCs activated with LMWH, showing higher anti-inflammatory and anti-fibrotic capability, and might be a promising candidate for SSc treatment[72]. IL-10-ASCs have been proven to have the capacity to suppress the development of HS by reducing inflammation during wound healing as well as the proliferation and migration of HSFs that produce ECM[73]. Poly(3-hydroxybutyrate-cohydroxy valerate) loaded with ASCs contains the bioactive cues required to improve wound healing and scarring[74].

***SVF***

SVF is an aqueous fraction that contains ASCs, EPCs, endothelial cells, macrophages, smooth muscle cells, lymphocytes, pericytes, and preadipocytes, among other components. The advantages of SVF over ASCs are thought to be in two areas. First, the heterogeneous cellular composition of SVF may be responsible for the superior therapeutic results seen in comparative animal studies. Second, in contrast to ASCs, SVF can be obtained significantly more quickly without the need for cell separation or special cultivation conditions. As a result, the therapeutic cellular product is relatively safe and is only required to meet minimal regulatory requirements[75]. However, it should be emphasized that whereas ASCs are useful for both allogeneic and autologous treatments, SVF is only appropriate for autologous treatments because it contains a variety of cell types that are known to trigger immunological rejection. hASCs have seemed to be more effective than SVF in HS, related to their higher levels of MMP-2 and MMP-2/tissue inhibitors of metalloproteinase-2 ratio, as well as higher expression of TGF-3 and HGF[76]. Whether SVF is indeed superior to ASCs in skin fibrosis treatment needs further research[6,77].

In addition to HS and keloids, SVF is also broadly applied clinically to scleroderma and SSc. SVF gel has superior anti-inflammatory and antifibrotic effects on scleroderma[78]. Moreover, SSc does not impair SVF's ability to heal vascular damage, hence justifying the use of this novel autologous biotherapy[79]. SVF injection is a potentially effective treatment that seems to last for at least one year. Quality of life, Raynaud's phenomenon, finger edema, and hand impairment and discomfort were significantly improved[80-83].

***Stem cell-free therapy***

The secretome of ASCs, with a focus on exosomes, appears to be a suitable and safe alternative with more effectiveness and fewer adverse effects due to restrictions on the use of stem cells in cell-based treatment. Moreover, the ability to biobank the ASC secretome is a significant benefit of cell-free therapy. In this review, we concentrate on the current understanding of the secretome of ASCs, such as ASC exosomes (ASC-Exos) and ASC-CM, used in skin fibrosis stem cell-free therapy (Figure 3).

**ASC-Exo:** As one of the components of paracrine signaling, ASC-Exos are small, single membranous secretory organelles rich in proteins, lipids, nucleic acids, and carbohydrate conjugates[26,84,85]. Among other research discoveries, they are thought to have a variety of activities, such as reshaping the ECM and transmitting signals and molecules to other cells. In addition, they are not rejected by the immune system, have homing effects, and the dose is easily controlled[86,87]. Compared to ASCs, ASC-Exos offer a great opportunity to create new cell-free therapeutic techniques that could circumvent the challenges and dangers related to using natural or synthetic stem cells[86,88].

ASC-Exos release miR-29a-3p, which can suppress the expression of several profibrotic, antiapoptotic, remodeling, and methylase genes[89]. ASC-Exos are now a viable new option for the systemic treatment of keloids. They significantly suppress the development of ECM in keloids by decreasing collagen synthesis and impairing the microvessel structure, enhancing the expression of TGF-3 while inhibiting the protein expression of Smad3 and Notch-1[84]. By suppressing the expression of the TGF-1/Smad pathway, ASC-EXOs may prevent keloid fibroblasts from proliferating and migrating and consequently promoting death[90].

In hypertrophic scar fibrosis, ASC-exosomal miR-192-5p targeted IL-17RA to control the Smad pathway, and miR-29a inhibited the TGF-2/Smad3 signaling pathway, which could be responsible for the antifibrotic effects[91,92]. Another postoperative study showed that hASC-Exo therapy inhibited collagen deposition and myofibroblast aggregation *in vivo* and reduced the development of HS[93].

**ASC-CM:** Active chemicals released by ASCs, such as cytokines, exovesicles, exosomes, DNA, and RNA, are found in ASC-CM and can facilitate tissue healing and control immunity. ASC-CM can lower treatment costs and avoid the safety issues associated with stem cell therapy[94]. One disadvantage of CM over stem cells is the short life of active components. Stem cells can anchor inside a tissue or organ after local administration and function there for a long time, but CM-containing substances such as growth or enzyme factors are rapidly diluted and eliminated by diffusion[95,52].

ASC-CM may reduce collagen deposition and scar formation, inhibiting the p38/mitogen-activated protein kinase signaling pathway can have an anti-scarring effect, and the use of ASC-CM may offer a unique therapeutic approach for the treatment of HS[96]. According to *in vitro* and *ex vivo* experiments, chyle fat-derived stem cell-CM reduced the expression of type I collagen (Col1), type III collagen (Col3), and SMA, which prevents fibrosis in HSFs[63]. ASCs-CM dramatically elevated MMP-1 expression and dose-dependently decreased cell survival, expression of fibrosis markers, tissue inhibitor of metalloproteinases-1, the amount of collagen produced, and the ratio of Col1/Col3. These findings show that ASC-CM efficiently blocks fibrosis-related factors and controls ECM remodeling in HSF[64]. Combining ASC-CM with therapeutic therapies is another development. A histologic study revealed that ASC-CM increased the density of cutaneous collagen and elastin and arranged them in a certain order. A good combination therapy for treating atrophic acne scars and skin rejuvenation is ASC-CM with FxCR[97]. Stronger antifibrotic effects of CD74+ ASC-conditioned media may have resulted from increased production of HGF, FGF2, and TGF-3 and lower levels of TGF-β1[69]. ASC-CM and polysaccharide hydrogels might cross-bind in situ, which could significantly improve the therapeutic results by reducing scar proliferation, offering a promising alternative for the prevention of HS[98].

**Updates on the clinical applications of ASC therapy**

To evaluate the effectiveness of ASCs, numerous clinical trials have been carried out; however, they have largely focused on SSCs. More research is required to determine the long-term safety of ASCs, detailed mechanisms of effect, and the capacity to translate experimental results into clinical practice.

ASCs are used to treat secondary-progressive multiple sclerosis in 30 individuals. However, assessments of treatment efficacy revealed a mild tendency toward effectiveness. Establishing the possible therapeutic benefit of this technique would require larger studies and presumably treatment at earlier stages[99].

To compare the effectiveness of an injection of ASC-SVF derived from adipose tissue with placebo in decreasing hand disability in 40 SSc patients. This research demonstrated a gradual improvement with no evidence that the AD-SVF was superior. Given the limitations of this trial, a study with a larger group of patients is urgently needed to accurately determine the value of ASC-SVF therapy[100]. It was revealed through a randomized controlled trial that regional adipose tissue grafting is beneficial in repairing ischemia digital ulcers in SSc[101].

This study investigates the safety and efficacy of administering autologous SVF cells to SSc patients. Early evaluations at six months suggest a possible efficacy that has to be confirmed in a larger population randomized placebo-controlled trial. Quality of life, Raynaud's phenomenon, finger edema, and hand impairment and discomfort are significantly improved[83]. A sequential 12-mo follow-up showed significant improvement in the vascular suppression score, skin sclerosis, motion and strength of the hands, and finger edema. The decrease in hand discomfort was statistically significant. A benefit was found in daily tasks, housework, and social activities, according to the questionnaire[82].

An open cohort study found that ASCs dramatically reduced the consequences of orofacial fibrosis in SSc. With the inhibition of fibroblast proliferation and important fibrogenesis regulators, including TG-1 and CTGF, ASCs may alleviate skin fibrosis[95].

**Safety assessment**

ASCs overcome the ethical issues associated with embryonic stem cells and are therefore considered safe. However, as a stem cell therapy, ASCs still have problems with storage and transport, as well as the risk of inducing tumors and malformations[102]. Further studies on their efficiency are yet needed, taking into account the host environment and patient-related factors. Importantly, a long-term follow-up is needed to supervise cancer recurrence rates in the context of previous malignancy[103].

**CONCLUSION**

While the underlying mechanism of skin fibrosis is still unclear, ASC therapy plays multiple roles in the treatment of skin fibrosis, with a combination of aesthetic and therapeutic outcomes. Different ASC derivatives show various properties, which might be further explored in clinical trials. In the future, ASC therapy is likely to become an indispensable part of combined treatment in skin fibrosis.

**REFERENCES**

1 **Berman B**, Maderal A, Raphael B. Keloids and Hypertrophic Scars: Pathophysiology, Classification, and Treatment. *Dermatol Surg* 2017; **43 Suppl 1**: S3-S18 [PMID: 27347634 DOI: 10.1097/DSS.0000000000000819]

2 **Santos A**, Lagares D. Matrix Stiffness: the Conductor of Organ Fibrosis. *Curr Rheumatol Rep* 2018; **20**: 2 [PMID: 29349703 DOI: 10.1007/s11926-018-0710-z]

3 **Coentro JQ**, Pugliese E, Hanley G, Raghunath M, Zeugolis DI. Current and upcoming therapies to modulate skin scarring and fibrosis. *Adv Drug Deliv Rev* 2019; **146**: 37-59 [PMID: 30172924 DOI: 10.1016/j.addr.2018.08.009]

4 **Ferreli C**, Gasparini G, Parodi A, Cozzani E, Rongioletti F, Atzori L. Cutaneous Manifestations of Scleroderma and Scleroderma-Like Disorders: a Comprehensive Review. *Clin Rev Allergy Immunol* 2017; **53**: 306-336 [PMID: 28712039 DOI: 10.1007/s12016-017-8625-4]

5 **Zuk PA**, Zhu M, Mizuno H, Huang J, Futrell JW, Katz AJ, Benhaim P, Lorenz HP, Hedrick MH. Multilineage cells from human adipose tissue: implications for cell-based therapies. *Tissue Eng* 2001; **7**: 211-228 [PMID: 11304456 DOI: 10.1089/107632701300062859]

6 **Bora P**, Majumdar AS. Adipose tissue-derived stromal vascular fraction in regenerative medicine: a brief review on biology and translation. *Stem Cell Res Ther* 2017; **8**: 145 [PMID: 28619097 DOI: 10.1186/s13287-017-0598-y]

7 **Guo X**, Schaudinn C, Blume-Peytavi U, Vogt A, Rancan F. Effects of Adipose-Derived Stem Cells and Their Conditioned Medium in a Human Ex Vivo Wound Model. *Cells* 2022; **11** [PMID: 35406762 DOI: 10.3390/cells11071198]

8 **Wang HC**, Dong R, Long X, Wang X. Aesthetic and therapeutic outcome of fat grafting for localized Scleroderma treatment: From basic study to clinical application. *J Cosmet Dermatol* 2021; **20**: 2723-2728 [PMID: 33486881 DOI: 10.1111/jocd.13941]

9 **Strong AL**, Rubin JP, Kozlow JH, Cederna PS. Fat Grafting for the Treatment of Scleroderma. *Plast Reconstr Surg* 2019; **144**: 1498-1507 [PMID: 31764674 DOI: 10.1097/PRS.0000000000006291]

10 **Daumas A**, Magalon J, Delaunay F, Abellan M, Philandrianos C, Sabatier F, Granel B, Magalon G. Fat Grafting for Treatment of Facial Scleroderma. *Clin Plast Surg* 2020; **47**: 155-163 [PMID: 31739892 DOI: 10.1016/j.cps.2019.08.016]

11 **Shaw TJ**, Kishi K, Mori R. Wound-associated skin fibrosis: mechanisms and treatments based on modulating the inflammatory response. *Endocr Metab Immune Disord Drug Targets* 2010; **10**: 320-330 [PMID: 20923404 DOI: 10.2174/1871530311006040320]

12 **Cutolo M**, Soldano S, Smith V. Pathophysiology of systemic sclerosis: current understanding and new insights. *Expert Rev Clin Immunol* 2019; **15**: 753-764 [PMID: 31046487 DOI: 10.1080/1744666X.2019.1614915]

13 **Ogawa R**. Keloid and Hypertrophic Scars Are the Result of Chronic Inflammation in the Reticular Dermis. *Int J Mol Sci* 2017; **18** [PMID: 28287424 DOI: 10.3390/ijms18030606]

14 **Ghazizadeh M**, Tosa M, Shimizu H, Hyakusoku H, Kawanami O. Functional implications of the IL-6 signaling pathway in keloid pathogenesis. *J Invest Dermatol* 2007; **127**: 98-105 [PMID: 17024100 DOI: 10.1038/sj.jid.5700564]

15 **Namazi MR**, Fallahzadeh MK, Schwartz RA. Strategies for prevention of scars: what can we learn from fetal skin? *Int J Dermatol* 2011; **50**: 85-93 [PMID: 21039435 DOI: 10.1111/j.1365-4632.2010.04678.x]

16 **Wang ZC**, Zhao WY, Cao Y, Liu YQ, Sun Q, Shi P, Cai JQ, Shen XZ, Tan WQ. The Roles of Inflammation in Keloid and Hypertrophic Scars. *Front Immunol* 2020; **11**: 603187 [PMID: 33343575 DOI: 10.3389/fimmu.2020.603187]

17 **Li J**, Cao J, Li M, Yu Y, Yang Y, Xiao X, Wu Z, Wang L, Tu Y, Chen H. Collagen triple helix repeat containing-1 inhibits transforming growth factor-b1-induced collagen type I expression in keloid. *Br J Dermatol* 2011; **164**: 1030-1036 [PMID: 21667528 DOI: 10.1111/j.1365-2133.2011.10215.x]

18 **Deng J**, Shi Y, Gao Z, Zhang W, Wu X, Cao W, Liu W. Inhibition of Pathological Phenotype of Hypertrophic Scar Fibroblasts Via Coculture with Adipose-Derived Stem Cells. *Tissue Eng Part A* 2018; **24**: 382-393 [PMID: 28562226 DOI: 10.1089/ten.TEA.2016.0550]

19 **Lee HJ**, Jang YJ. Recent Understandings of Biology, Prophylaxis and Treatment Strategies for Hypertrophic Scars and Keloids. *Int J Mol Sci* 2018; **19** [PMID: 29498630 DOI: 10.3390/ijms19030711]

20 **Ho YY**, Lagares D, Tager AM, Kapoor M. Fibrosis--a lethal component of systemic sclerosis. *Nat Rev Rheumatol* 2014; **10**: 390-402 [PMID: 24752182 DOI: 10.1038/nrrheum.2014.53]

21 **Denton CP**, Khanna D. Systemic sclerosis. *Lancet* 2017; **390**: 1685-1699 [PMID: 28413064 DOI: 10.1016/S0140-6736(17)30933-9]

22 **Perelas A**, Silver RM, Arrossi AV, Highland KB. Systemic sclerosis-associated interstitial lung disease. *Lancet Respir Med* 2020; **8**: 304-320 [PMID: 32113575 DOI: 10.1016/S2213-2600(19)30480-1]

23 **Skaug B**, Assassi S. Type I interferon dysregulation in Systemic Sclerosis. *Cytokine* 2020; **132**: 154635 [PMID: 30685202 DOI: 10.1016/j.cyto.2018.12.018]

24 **Jerjen R**, Nikpour M, Krieg T, Denton CP, Saracino AM. Systemic sclerosis in adults. Part I: Clinical features and pathogenesis. *J Am Acad Dermatol* 2022; **87**: 937-954 [PMID: 35131402 DOI: 10.1016/j.jaad.2021.10.065]

25 **Bukiri H**, Volkmann ER. Current advances in the treatment of systemic sclerosis. *Curr Opin Pharmacol* 2022; **64**: 102211 [PMID: 35447517 DOI: 10.1016/j.coph.2022.102211]

26 **Bacakova L**, Zarubova J, Travnickova M, Musilkova J, Pajorova J, Slepicka P, Kasalkova NS, Svorcik V, Kolska Z, Motarjemi H, Molitor M. Stem cells: their source, potency and use in regenerative therapies with focus on adipose-derived stem cells - a review. *Biotechnol Adv* 2018; **36**: 1111-1126 [PMID: 29563048 DOI: 10.1016/j.biotechadv.2018.03.011]

27 **Al-Ghadban S**, Bunnell BA. Adipose Tissue-Derived Stem Cells: Immunomodulatory Effects and Therapeutic Potential. *Physiology (Bethesda)* 2020; **35**: 125-133 [PMID: 32027561 DOI: 10.1152/physiol.00021.2019]

28 **Suh A**, Pham A, Cress MJ, Pincelli T, TerKonda SP, Bruce AJ, Zubair AC, Wolfram J, Shapiro SA. Adipose-derived cellular and cell-derived regenerative therapies in dermatology and aesthetic rejuvenation. *Ageing Res Rev* 2019; **54**: 100933 [PMID: 31247326 DOI: 10.1016/j.arr.2019.100933]

29 **Ankrum JA**, Ong JF, Karp JM. Mesenchymal stem cells: immune evasive, not immune privileged. *Nat Biotechnol* 2014; **32**: 252-260 [PMID: 24561556 DOI: 10.1038/nbt.2816]

30 **Maria AT**, Toupet K, Maumus M, Fonteneau G, Le Quellec A, Jorgensen C, Guilpain P, Noël D. Human adipose mesenchymal stem cells as potent anti-fibrosis therapy for systemic sclerosis. *J Autoimmun* 2016; **70**: 31-39 [PMID: 27052182 DOI: 10.1016/j.jaut.2016.03.013]

31 **Vizoso FJ**, Eiro N, Cid S, Schneider J, Perez-Fernandez R. Mesenchymal Stem Cell Secretome: Toward Cell-Free Therapeutic Strategies in Regenerative Medicine. *Int J Mol Sci* 2017; **18** [PMID: 28841158 DOI: 10.3390/ijms18091852]

32 **Usunier B**, Benderitter M, Tamarat R, Chapel A. Management of fibrosis: the mesenchymal stromal cells breakthrough. *Stem Cells Int* 2014; **2014**: 340257 [PMID: 25132856 DOI: 10.1155/2014/340257]

33 **Rubio GA**, Elliot SJ, Wikramanayake TC, Xia X, Pereira-Simon S, Thaller SR, Glinos GD, Jozic I, Hirt P, Pastar I, Tomic-Canic M, Glassberg MK. Mesenchymal stromal cells prevent bleomycin-induced lung and skin fibrosis in aged mice and restore wound healing. *J Cell Physiol* 2018; **233**: 5503-5512 [PMID: 29271488 DOI: 10.1002/jcp.26418]

34 **Wang J**, Cai J, Zhang Q, Wen J, Liao Y, Lu F. Fat transplantation induces dermal adipose regeneration and reverses skin fibrosis through dedifferentiation and redifferentiation of adipocytes. *Stem Cell Res Ther* 2022; **13**: 499 [PMID: 36210466 DOI: 10.1186/s13287-022-03127-0]

35 **Kilroy GE**, Foster SJ, Wu X, Ruiz J, Sherwood S, Heifetz A, Ludlow JW, Stricker DM, Potiny S, Green P, Halvorsen YD, Cheatham B, Storms RW, Gimble JM. Cytokine profile of human adipose-derived stem cells: expression of angiogenic, hematopoietic, and pro-inflammatory factors. *J Cell Physiol* 2007; **212**: 702-709 [PMID: 17477371 DOI: 10.1002/jcp.21068]

36 **Tratwal J**, Mathiasen AB, Juhl M, Brorsen SK, Kastrup J, Ekblond A. Influence of vascular endothelial growth factor stimulation and serum deprivation on gene activation patterns of human adipose tissue-derived stromal cells. *Stem Cell Res Ther* 2015; **6**: 62 [PMID: 25889587 DOI: 10.1186/s13287-015-0062-9]

37 **Blaber SP**, Webster RA, Hill CJ, Breen EJ, Kuah D, Vesey G, Herbert BR. Analysis of in vitro secretion profiles from adipose-derived cell populations. *J Transl Med* 2012; **10**: 172 [PMID: 22913454 DOI: 10.1186/1479-5876-10-172]

38 **Ma T**, Fu B, Yang X, Xiao Y, Pan M. Adipose mesenchymal stem cell-derived exosomes promote cell proliferation, migration, and inhibit cell apoptosis via Wnt/β-catenin signaling in cutaneous wound healing. *J Cell Biochem* 2019; **120**: 10847-10854 [PMID: 30681184 DOI: 10.1002/jcb.28376]

39 **Kim WS**, Park BS, Sung JH, Yang JM, Park SB, Kwak SJ, Park JS. Wound healing effect of adipose-derived stem cells: a critical role of secretory factors on human dermal fibroblasts. *J Dermatol Sci* 2007; **48**: 15-24 [PMID: 17643966 DOI: 10.1016/j.jdermsci.2007.05.018]

40 **Nguyen A**, Guo J, Banyard DA, Fadavi D, Toranto JD, Wirth GA, Paydar KZ, Evans GR, Widgerow AD. Stromal vascular fraction: A regenerative reality? Part 1: Current concepts and review of the literature. *J Plast Reconstr Aesthet Surg* 2016; **69**: 170-179 [PMID: 26565755 DOI: 10.1016/j.bjps.2015.10.015]

41 **Sharma S**, Muthu S, Jeyaraman M, Ranjan R, Jha SK. Translational products of adipose tissue-derived mesenchymal stem cells: Bench to bedside applications. *World J Stem Cells* 2021; **13**: 1360-1381 [PMID: 34786149 DOI: 10.4252/wjsc.v13.i10.1360]

42 **Strioga M**, Viswanathan S, Darinskas A, Slaby O, Michalek J. Same or not the same? Comparison of adipose tissue-derived versus bone marrow-derived mesenchymal stem and stromal cells. *Stem Cells Dev* 2012; **21**: 2724-2752 [PMID: 22468918 DOI: 10.1089/scd.2011.0722]

43 **Zhao S**, Wehner R, Bornhäuser M, Wassmuth R, Bachmann M, Schmitz M. Immunomodulatory properties of mesenchymal stromal cells and their therapeutic consequences for immune-mediated disorders. *Stem Cells Dev* 2010; **19**: 607-614 [PMID: 19824807 DOI: 10.1089/scd.2009.0345]

44 **Ejaz A**, Epperly MW, Hou W, Greenberger JS, Rubin JP. Adipose-Derived Stem Cell Therapy Ameliorates Ionizing Irradiation Fibrosis via Hepatocyte Growth Factor-Mediated Transforming Growth Factor-β Downregulation and Recruitment of Bone Marrow Cells. *Stem Cells* 2019; **37**: 791-802 [PMID: 30861238 DOI: 10.1002/stem.3000]

45 **Deng S**, Zhou X, Ge Z, Song Y, Wang H, Liu X, Zhang D. Exosomes from adipose-derived mesenchymal stem cells ameliorate cardiac damage after myocardial infarction by activating S1P/SK1/S1PR1 signaling and promoting macrophage M2 polarization. *Int J Biochem Cell Biol* 2019; **114**: 105564 [PMID: 31276786 DOI: 10.1016/j.biocel.2019.105564]

46 **Wang J**, Liao Y, Xia J, Wang Z, Mo X, Feng J, He Y, Chen X, Li Y, Lu F, Cai J. Mechanical micronization of lipoaspirates for the treatment of hypertrophic scars. *Stem Cell Res Ther* 2019; **10**: 42 [PMID: 30678729 DOI: 10.1186/s13287-019-1140-1]

47 **Huang SH**, Wu SH, Lee SS, Chang KP, Chai CY, Yeh JL, Lin SD, Kwan AL, David Wang HM, Lai CS. Fat Grafting in Burn Scar Alleviates Neuropathic Pain via Anti-Inflammation Effect in Scar and Spinal Cord. *PLoS One* 2015; **10**: e0137563 [PMID: 26368011 DOI: 10.1371/journal.pone.0137563]

48 **Okamura A**, Matsushita T, Komuro A, Kobayashi T, Maeda S, Hamaguchi Y, Takehara K. Adipose-derived stromal/stem cells successfully attenuate the fibrosis of scleroderma mouse models. *Int J Rheum Dis* 2020; **23**: 216-225 [PMID: 31808305 DOI: 10.1111/1756-185X.13764]

49 **Chen P**, Ning X, Li W, Pan Y, Wang L, Li H, Fan X, Zhang J, Luo T, Wu Y, Ou C, Chen M. Fabrication of Tβ4-Exosome-releasing artificial stem cells for myocardial infarction therapy by improving coronary collateralization. *Bioact Mater* 2022; **14**: 416-429 [PMID: 35386821 DOI: 10.1016/j.bioactmat.2022.01.029]

50 **Rocha LA**, Gomes ED, Afonso JL, Granja S, Baltazar F, Silva NA, Shoichet MS, Sousa RA, Learmonth DA, Salgado AJ. In vitro Evaluation of ASCs and HUVECs Co-cultures in 3D Biodegradable Hydrogels on Neurite Outgrowth and Vascular Organization. *Front Cell Dev Biol* 2020; **8**: 489 [PMID: 32612997 DOI: 10.3389/fcell.2020.00489]

51 **Dolmans MM**, Cacciottola L, Amorim CA, Manavella D. Translational research aiming to improve survival of ovarian tissue transplants using adipose tissue-derived stem cells. *Acta Obstet Gynecol Scand* 2019; **98**: 665-671 [PMID: 30891730 DOI: 10.1111/aogs.13610]

52 **Cavallari G**, Olivi E, Bianchi F, Neri F, Foroni L, Valente S, La Manna G, Nardo B, Stefoni S, Ventura C. Mesenchymal stem cells and islet cotransplantation in diabetic rats: improved islet graft revascularization and function by human adipose tissue-derived stem cells preconditioned with natural molecules. *Cell Transplant* 2012; **21**: 2771-2781 [PMID: 22472472 DOI: 10.3727/096368912X637046]

53 **Carstens MH**, Mendieta M, Pérez C, Villareal E, Garcia R. Assisted Salvage of Ischemic Fasciocutaneous Flap Using Adipose-Derived Mesenchymal Stem Cells: In-Situ Revascularization. *Aesthet Surg J* 2017; **37**: S38-S45 [PMID: 29025216 DOI: 10.1093/asj/sjx052]

54 **Bura A**, Planat-Benard V, Bourin P, Silvestre JS, Gross F, Grolleau JL, Saint-Lebese B, Peyrafitte JA, Fleury S, Gadelorge M, Taurand M, Dupuis-Coronas S, Leobon B, Casteilla L. Phase I trial: the use of autologous cultured adipose-derived stroma/stem cells to treat patients with non-revascularizable critical limb ischemia. *Cytotherapy* 2014; **16**: 245-257 [PMID: 24438903 DOI: 10.1016/j.jcyt.2013.11.011]

55 **Kisseleva T**, Brenner D. Molecular and cellular mechanisms of liver fibrosis and its regression. *Nat Rev Gastroenterol Hepatol* 2021; **18**: 151-166 [PMID: 33128017 DOI: 10.1038/s41575-020-00372-7]

56 **Hinz B**. Masters and servants of the force: the role of matrix adhesions in myofibroblast force perception and transmission. *Eur J Cell Biol* 2006; **85**: 175-181 [PMID: 16546559 DOI: 10.1016/j.ejcb.2005.09.004]

57 **Lee SH**. Human Adipose-Derived Stem Cells' Paracrine Factors in Conditioned Medium Can Enhance Porcine Oocyte Maturation and Subsequent Embryo Development. *Int J Mol Sci* 2021; **22** [PMID: 33430095 DOI: 10.3390/ijms22020579]

58 **Abou Eitta RS**, Ismail AA, Abdelmaksoud RA, Ghezlan NA, Mehanna RA. Evaluation of autologous adipose-derived stem cells vs. fractional carbon dioxide laser in the treatment of post acne scars: a split-face study. *Int J Dermatol* 2019; **58**: 1212-1222 [PMID: 31297798 DOI: 10.1111/ijd.14567]

59 **Zhang Q**, Liu LN, Yong Q, Deng JC, Cao WG. Intralesional injection of adipose-derived stem cells reduces hypertrophic scarring in a rabbit ear model. *Stem Cell Res Ther* 2015; **6**: 145 [PMID: 26282394 DOI: 10.1186/s13287-015-0133-y]

60 **Liu J**, Ren J, Su L, Cheng S, Zhou J, Ye X, Dong Y, Sun S, Qi F, Liu Z, Pleat J, Zhai H, Zhu N. Human adipose tissue-derived stem cells inhibit the activity of keloid fibroblasts and fibrosis in a keloid model by paracrine signaling. *Burns* 2018; **44**: 370-385 [PMID: 29029852 DOI: 10.1016/j.burns.2017.08.017]

61 **Wu B**, Feng J, Guo J, Wang J, Xiu G, Xu J, Ning K, Ling B, Fu Q, Xu J. ADSCs-derived exosomes ameliorate hepatic fibrosis by suppressing stellate cell activation and remodeling hepatocellular glutamine synthetase-mediated glutamine and ammonia homeostasis. *Stem Cell Res Ther* 2022; **13**: 494 [PMID: 36195966 DOI: 10.1186/s13287-022-03049-x]

62 **Bonnans C**, Chou J, Werb Z. Remodelling the extracellular matrix in development and disease. *Nat Rev Mol Cell Biol* 2014; **15**: 786-801 [PMID: 25415508 DOI: 10.1038/nrm3904]

63 **Chen J**, Li Z, Huang Z, Liang L, Chen M. Chyle Fat-Derived Stem Cells Conditioned Medium Inhibits Hypertrophic Scar Fibroblast Activity. *Ann Plast Surg* 2019; **83**: 271-277 [PMID: 31149905 DOI: 10.1097/SAP.0000000000001932]

64 **Ma J**, Yan X, Lin Y, Tan Q. Hepatocyte Growth Factor Secreted from Human Adipose-Derived Stem Cells Inhibits Fibrosis in Hypertrophic Scar Fibroblasts. *Curr Mol Med* 2020; **20**: 558-571 [PMID: 31903876 DOI: 10.2174/1566524020666200106095745]

65 **Han B**, Fan J, Liu L, Tian J, Gan C, Yang Z, Jiao H, Zhang T, Liu Z, Zhang H. Adipose-derived mesenchymal stem cells treatments for fibroblasts of fibrotic scar via downregulating TGF-β1 and Notch-1 expression enhanced by photobiomodulation therapy. *Lasers Med Sci* 2019; **34**: 1-10 [PMID: 30367294 DOI: 10.1007/s10103-018-2567-9]

66 **Søndergaard RH**, Højgaard LD, Reese-Petersen AL, Hoeeg C, Mathiasen AB, Haack-Sørensen M, Follin B, Genovese F, Kastrup J, Juhl M, Ekblond A. Adipose-derived stromal cells increase the formation of collagens through paracrine and juxtacrine mechanisms in a fibroblast co-culture model utilizing macromolecular crowding. *Stem Cell Res Ther* 2022; **13**: 250 [PMID: 35690799 DOI: 10.1186/s13287-022-02923-y]

67 **Yun IS**, Jeon YR, Lee WJ, Lee JW, Rah DK, Tark KC, Lew DH. Effect of human adipose derived stem cells on scar formation and remodeling in a pig model: a pilot study. *Dermatol Surg* 2012; **38**: 1678-1688 [PMID: 22804839 DOI: 10.1111/j.1524-4725.2012.02495.x]

68 **Foubert P**, Zafra D, Liu M, Rajoria R, Gutierrez D, Tenenhaus M, Fraser JK. Autologous adipose-derived regenerative cell therapy modulates development of hypertrophic scarring in a red Duroc porcine model. *Stem Cell Res Ther* 2017; **8**: 261 [PMID: 29141687 DOI: 10.1186/s13287-017-0704-1]

69 **Borrelli MR**, Patel RA, Adem S, Diaz Deleon NM, Shen AH, Sokol J, Yen S, Chang EY, Nazerali R, Nguyen D, Momeni A, Wang KC, Longaker MT, Wan DC. The antifibrotic adipose-derived stromal cell: Grafted fat enriched with CD74+ adipose-derived stromal cells reduces chronic radiation-induced skin fibrosis. *Stem Cells Transl Med* 2020; **9**: 1401-1413 [PMID: 32563212 DOI: 10.1002/sctm.19-0317]

70 **Xu M**, Fang S, Ma X. CD73(+) adipose-derived stem cells reduce scar formation through PLOD1. *Ann Transl Med* 2022; **10**: 66 [PMID: 35282129 DOI: 10.21037/atm-21-6557]

71 **Rong S**, Li C, Li S, Wu S, Sun F. Genetically modified adipose-derived stem cells with matrix metalloproteinase 3 promote scarless cutaneous repair. *Dermatol Ther* 2020; **33**: e14112 [PMID: 32737916 DOI: 10.1111/dth.14112]

72 **Suzuka T**, Kotani T, Saito T, Matsuda S, Sato T, Takeuchi T. Therapeutic effects of adipose-derived mesenchymal stem/stromal cells with enhanced migration ability and hepatocyte growth factor secretion by low-molecular-weight heparin treatment in bleomycin-induced mouse models of systemic sclerosis. *Arthritis Res Ther* 2022; **24**: 228 [PMID: 36207753 DOI: 10.1186/s13075-022-02915-6]

73 **Xie F**, Teng L, Lu J, Xu J, Zhang C, Yang L, Ma X, Zhao M. Interleukin-10-Modified Adipose-Derived Mesenchymal Stem Cells Prevent Hypertrophic Scar Formation via Regulating the Biological Characteristics of Fibroblasts and Inflammation. *Mediators Inflamm* 2022; **2022**: 6368311 [PMID: 35774067 DOI: 10.1155/2022/6368311]

74 **Zonari A**, Martins TM, Paula AC, Boeloni JN, Novikoff S, Marques AP, Correlo VM, Reis RL, Goes AM. Polyhydroxybutyrate-co-hydroxyvalerate structures loaded with adipose stem cells promote skin healing with reduced scarring. *Acta Biomater* 2015; **17**: 170-181 [PMID: 25662911 DOI: 10.1016/j.actbio.2015.01.043]

75 **Daumas A**, Magalon J, Jouve E, Truillet R, Casanova D, Giraudo L, Veran J, Benyamine A, Dignat-George F, Magalon G, Sabatier F, Granel B. Long-term follow-up after autologous adipose-derived stromal vascular fraction injection into fingers in systemic sclerosis patients. *Curr Res Transl Med* 2017; **65**: 40-43 [PMID: 28340695 DOI: 10.1016/j.retram.2016.10.006]

76 **Domergue S**, Bony C, Maumus M, Toupet K, Frouin E, Rigau V, Vozenin MC, Magalon G, Jorgensen C, Noël D. Comparison between Stromal Vascular Fraction and Adipose Mesenchymal Stem Cells in Remodeling Hypertrophic Scars. *PLoS One* 2016; **11**: e0156161 [PMID: 27227960 DOI: 10.1371/journal.pone.0156161]

77 **Wang C**, Long X, Si L, Chen B, Zhang Y, Sun T, Zhang X, Zhao RC, Wang X. A pilot study on ex vivo expanded autologous adipose-derived stem cells of improving fat retention in localized scleroderma patients. *Stem Cells Transl Med* 2021; **10**: 1148-1156 [PMID: 33871949 DOI: 10.1002/sctm.20-0419]

78 **Serratrice N**, Bruzzese L, Magalon J, Véran J, Giraudo L, Aboudou H, Ould-Ali D, Nguyen PS, Bausset O, Daumas A, Casanova D, Granel B, Andrac-Meyer L, Sabatier F, Magalon G. New fat-derived products for treating skin-induced lesions of scleroderma in nude mice. *Stem Cell Res Ther* 2014; **5**: 138 [PMID: 25519759 DOI: 10.1186/scrt528]

79 **Magalon J**, Velier M, Simoncini S, François P, Bertrand B, Daumas A, Benyamine A, Boissier R, Arnaud L, Lyonnet L, Fernandez S, Dignat-George F, Casanova D, Guillet B, Granel B, Paul P, Sabatier F. Molecular profile and proangiogenic activity of the adipose-derived stromal vascular fraction used as an autologous innovative medicinal product in patients with systemic sclerosis. *Ann Rheum Dis* 2019; **78**: 391-398 [PMID: 30612118 DOI: 10.1136/annrheumdis-2018-214218]

80 **Lee JW**, Park SH, Lee SJ, Kim SH, Suh IS, Jeong HS. Clinical Impact of Highly Condensed Stromal Vascular Fraction Injection in Surgical Management of Depressed and Contracted Scars. *Aesthetic Plast Surg* 2018; **42**: 1689-1698 [PMID: 30191279 DOI: 10.1007/s00266-018-1216-9]

81 **Jiang W**, Wang J, Lin J, Jiang S, Quan Y, Liao Y, Gao J, Cai J. Adipose-Derived Stem Cell-Enriched Lipotransfer Reverses Skin Sclerosis by Suppressing Dermal Inflammation. *Plast Reconstr Surg* 2022; **150**: 578-587 [PMID: 35759642 DOI: 10.1097/PRS.0000000000009435]

82 **Guillaume-Jugnot P**, Daumas A, Magalon J, Jouve E, Nguyen PS, Truillet R, Mallet S, Casanova D, Giraudo L, Veran J, Dignat-George F, Sabatier F, Magalon G, Granel B. Autologous adipose-derived stromal vascular fraction in patients with systemic sclerosis: 12-month follow-up. *Rheumatology (Oxford)* 2016; **55**: 301-306 [PMID: 26350489 DOI: 10.1093/rheumatology/kev323]

83 **Granel B**, Daumas A, Jouve E, Harlé JR, Nguyen PS, Chabannon C, Colavolpe N, Reynier JC, Truillet R, Mallet S, Baiada A, Casanova D, Giraudo L, Arnaud L, Veran J, Sabatier F, Magalon G. Safety, tolerability and potential efficacy of injection of autologous adipose-derived stromal vascular fraction in the fingers of patients with systemic sclerosis: an open-label phase I trial. *Ann Rheum Dis* 2015; **74**: 2175-2182 [PMID: 25114060 DOI: 10.1136/annrheumdis-2014-205681]

84 **Li J**, Li Z, Wang S, Bi J, Huo R. Exosomes from human adipose-derived mesenchymal stem cells inhibit production of extracellular matrix in keloid fibroblasts via downregulating transforming growth factor-β2 and Notch-1 expression. *Bioengineered* 2022; **13**: 8515-8525 [PMID: 35333672 DOI: 10.1080/21655979.2022.2051838]

85 **Abels ER**, Breakefield XO. Introduction to Extracellular Vesicles: Biogenesis, RNA Cargo Selection, Content, Release, and Uptake. *Cell Mol Neurobiol* 2016; **36**: 301-312 [PMID: 27053351 DOI: 10.1007/s10571-016-0366-z]

86 **Baglio SR**, Pegtel DM, Baldini N. Mesenchymal stem cell secreted vesicles provide novel opportunities in (stem) cell-free therapy. *Front Physiol* 2012; **3**: 359 [PMID: 22973239 DOI: 10.3389/fphys.2012.00359]

87 **Stoorvogel W**, Kleijmeer MJ, Geuze HJ, Raposo G. The biogenesis and functions of exosomes. *Traffic* 2002; **3**: 321-330 [PMID: 11967126 DOI: 10.1034/j.1600-0854.2002.30502.x]

88 **Rozier P**, Maumus M, Bony C, Maria ATJ, Sabatier F, Jorgensen C, Guilpain P, Noël D. Extracellular Vesicles Are More Potent Than Adipose Mesenchymal Stromal Cells to Exert an Anti-Fibrotic Effect in an In Vitro Model of Systemic Sclerosis. *Int J Mol Sci* 2021; **22** [PMID: 34202139 DOI: 10.3390/ijms22136837]

89 **Rozier P**, Maumus M, Maria ATJ, Toupet K, Lai-Kee-Him J, Jorgensen C, Guilpain P, Noël D. Mesenchymal stromal cells-derived extracellular vesicles alleviate systemic sclerosis via miR-29a-3p. *J Autoimmun* 2021; **121**: 102660 [PMID: 34020253 DOI: 10.1016/j.jaut.2021.102660]

90 **Wu ZY**, Zhang HJ, Zhou ZH, Li ZP, Liao SM, Wu ZY, Huang HH, Shi YC. The effect of inhibiting exosomes derived from adipose-derived stem cells via the TGF-β1/Smad pathway on the fibrosis of keloid fibroblasts. *Gland Surg* 2021; **10**: 1046-1056 [PMID: 33842249 DOI: 10.21037/gs-21-4]

91 **Yuan R**, Dai X, Li Y, Li C, Liu L. Exosomes from miR-29a-modified adipose-derived mesenchymal stem cells reduce excessive scar formation by inhibiting TGF-β2/Smad3 signaling. *Mol Med Rep* 2021; **24** [PMID: 34476508 DOI: 10.3892/mmr.2021.12398]

92 **Li Y**, Zhang J, Shi J, Liu K, Wang X, Jia Y, He T, Shen K, Wang Y, Liu J, Zhang W, Wang H, Zheng Z, Hu D. Exosomes derived from human adipose mesenchymal stem cells attenuate hypertrophic scar fibrosis by miR-192-5p/IL-17RA/Smad axis. *Stem Cell Res Ther* 2021; **12**: 221 [PMID: 33789737 DOI: 10.1186/s13287-021-02290-0]

93 **Zhu YZ**, Hu X, Zhang J, Wang ZH, Wu S, Yi YY. Extracellular Vesicles Derived From Human Adipose-Derived Stem Cell Prevent the Formation of Hypertrophic Scar in a Rabbit Model. *Ann Plast Surg* 2020; **84**: 602-607 [PMID: 32282497 DOI: 10.1097/SAP.0000000000002357]

94 **Zhang B**, Wu Y, Mori M, Yoshimura K. Adipose-Derived Stem Cell Conditioned Medium and Wound Healing: A Systematic Review. *Tissue Eng Part B Rev* 2022; **28**: 830-847 [PMID: 34409890 DOI: 10.1089/ten.TEB.2021.0100]

95 **Almadori A**, Griffin M, Ryan CM, Hunt DF, Hansen E, Kumar R, Abraham DJ, Denton CP, Butler PEM. Stem cell enriched lipotransfer reverses the effects of fibrosis in systemic sclerosis. *PLoS One* 2019; **14**: e0218068 [PMID: 31314805 DOI: 10.1371/journal.pone.0218068]

96 **Li Y**, Zhang W, Gao J, Liu J, Wang H, Li J, Yang X, He T, Guan H, Zheng Z, Han S, Dong M, Han J, Shi J, Hu D. Adipose tissue-derived stem cells suppress hypertrophic scar fibrosis via the p38/MAPK signaling pathway. *Stem Cell Res Ther* 2016; **7**: 102 [PMID: 27484727 DOI: 10.1186/s13287-016-0356-6]

97 **Zhou BR**, Zhang T, Bin Jameel AA, Xu Y, Xu Y, Guo SL, Wang Y, Permatasari F, Luo D. The efficacy of conditioned media of adipose-derived stem cells combined with ablative carbon dioxide fractional resurfacing for atrophic acne scars and skin rejuvenation. *J Cosmet Laser Ther* 2016; **18**: 138-148 [PMID: 26735291 DOI: 10.3109/14764172.2015.1114638]

98 **Zhang C**, Wang T, Zhang L, Chen P, Tang S, Chen A, Li M, Peng G, Gao H, Weng H, Zhang H, Li S, Chen J, Chen L, Chen X. Combination of lyophilized adipose-derived stem cell concentrated conditioned medium and polysaccharide hydrogel in the inhibition of hypertrophic scarring. *Stem Cell Res Ther* 2021; **12**: 23 [PMID: 33413617 DOI: 10.1186/s13287-020-02061-3]

99 **Fernández O**, Izquierdo G, Fernández V, Leyva L, Reyes V, Guerrero M, León A, Arnaiz C, Navarro G, Páramo MD, Cuesta A, Soria B, Hmadcha A, Pozo D, Fernandez-Montesinos R, Leal M, Ochotorena I, Gálvez P, Geniz MA, Barón FJ, Mata R, Medina C, Caparrós-Escudero C, Cardesa A, Cuende N; Research Group Study EudraCT 2008-004015-35. Adipose-derived mesenchymal stem cells (AdMSC) for the treatment of secondary-progressive multiple sclerosis: A triple blinded, placebo controlled, randomized phase I/II safety and feasibility study. *PLoS One* 2018; **13**: e0195891 [PMID: 29768414 DOI: 10.1371/journal.pone.0195891]

100 **Daumas A**, Magalon J, Jouve E, Casanova D, Philandrianos C, Abellan Lopez M, Mallet S, Veran J, Auquit-Auckbur I, Farge D, Levesque H, Benhamou Y, Arnaud L, Giraudo L, Dumoulin C, Giverne C, Boyer O, Giuliani A, Bourgarel V, Harlé JR, Schleinitz N, Brunet J, Pers YM, Ferreira R, Cras A, Boccara D, Larghero J, Château J, Hot A, Dignat-George F, Magalon G, Sabatier F, Granel B. Adipose tissue-derived stromal vascular fraction for treating hands of patients with systemic sclerosis: a multicentre randomized trial Autologous AD-SVF versus placebo in systemic sclerosis. *Rheumatology (Oxford)* 2022; **61**: 1936-1947 [PMID: 34297066 DOI: 10.1093/rheumatology/keab584]

101 **Del Papa N**, Di Luca G, Andracco R, Zaccara E, Maglione W, Pignataro F, Minniti A, Vitali C. Regional grafting of autologous adipose tissue is effective in inducing prompt healing of indolent digital ulcers in patients with systemic sclerosis: results of a monocentric randomized controlled study. *Arthritis Res Ther* 2019; **21**: 7 [PMID: 30616671 DOI: 10.1186/s13075-018-1792-8]

102 **Trounson A**, McDonald C. Stem Cell Therapies in Clinical Trials: Progress and Challenges. *Cell Stem Cell* 2015; **17**: 11-22 [PMID: 26140604 DOI: 10.1016/j.stem.2015.06.007]

103 **Luan A**, Duscher D, Whittam AJ, Paik KJ, Zielins ER, Brett EA, Atashroo DA, Hu MS, Lee GK, Gurtner GC, Longaker MT, Wan DC. Cell-Assisted Lipotransfer Improves Volume Retention in Irradiated Recipient Sites and Rescues Radiation-Induced Skin Changes. *Stem Cells* 2016; **34**: 668-673 [PMID: 26661694 DOI: 10.1002/stem.2256]

**Footnotes**

**Conflict-of-interest statement:** All theauthors report no relevant conflicts of interest for this article.

**Open-Access:** This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/

**Provenance and peer review:** Unsolicited article; Externally peer reviewed.

**Peer-review model:** Single blind

**Peer-review started:** December 28, 2022

**First decision:** March 10, 2023

**Article in press:**

**Specialty type:** Cell and tissue engineering

**Country/Territory of origin:** China

**Peer-review report’s scientific quality classification**

Grade A (Excellent): 0

Grade B (Very good): 0

Grade C (Good): C, C

Grade D (Fair): 0

Grade E (Poor): 0

**P-Reviewer:** Kamarudin TA, Malaysia; Maslennikov R, Russia **S-Editor:** Fan JR **L-Editor:** A **P-Editor:**

**Figure Legends**



**Figure 1 The brief mechanism of adipose-derived stem cell therapy in skin fibrosis.** ECM: Extracellular matrix; ASC: Adipose-derived stem cell; HGF: Hepatocyte growth factor; IGFBP-rp1/IGFBP-7: Insulin-like growth factor binding protein-related protein-1/Insulin-like growth factor-binding protein-7; EDA-A2: Ectodysplasin-A2; IL-10: Interleukin 10; IL-4: Interleukin 4; IL-1β: Interleukin 1β; TGF-β: Transforming growth factor beta; PGE2: Prostaglandin E2. Figure 1 is created with BioRender.com.



**Figure 2 The culture and classification of adipose-derived stem cells and their derivatives.** A: Culture of adipose-derived stem cells (ASC) and their derivatives; B: Classification of ASC and their derivatives. EPCs: Endothelial precursor cells; ECM: extracellular matrix; Exo: Exosomes; ASC: Adipose-derived stem cell; ASC-CM: ASC-conditioned medium; ASC-Exo: ASC exosomes; SVF: Stromal vascular fraction. Figure 2 is created by Figdraw.



**Figure 3** **Adipose-derived stem cell conditioned media, exosomes, and adipose tissue extracts synthesis and therapeutic application.** ASC: Adipose-derived stem cell; ASC-CM: ASC-conditioned medium; ASC-Exo: ASC exosomes; FBS: fetal bovine serum; PBS: Phosphate-buffered saline. Figure 3 is created with BioRender.com.